



# Kentucky Medicaid Drug Management Review Advisory Board (DMRAB) Meeting

Tina Hawkins, PharmD  
Clinical Program Manager  
May 12, 2011



# Agenda



- Welcome and Establishment of Quorum
- Approval of the November 4, 2010 Meeting Minutes
- New Business
  - Population Statistics
  - Utilization Data
  - ProDUR
  - Severity Level I Drug-to-Drug Interactions
  - RetroDUR
  - Future DUR Activities
- Public Comment
- Adjournment

# Pharmacy Data

- Population Statistics
- Utilization Data
  - Total Population
  - Adult Population (age 19 and above)
  - Child Population (ages 0 through 18)
- Utilization by Disease States
  - Total Population
  - Adult Population (age 19 and above)
  - Child Population (ages 0 through 18)
- Top 10 Prescribers

# Population

	1Q2011	1Q2010
Non-Dual Children (<19)	344,675	334,778
Non-Dual Adults (≥19) with Rx Limit	163,012	157,760
Dual Eligible Children	146	158
Dual Eligible Adults	92,106	87,614
Total Medicaid Population	599,939	580,310
Ave Pharmacy Utilizing Members per month < 19 (Children)	130,646	115,677
Ave Pharmacy Utilizing Members per month ≥19 (Adults)	135,773	134,487

# Utilizing Members

	1Q2011	1Q2010
# Utilizing Members / Month	266,199	250,107
# Prescriptions / Month	991,302	944,353
Total Amount Paid / Month	\$55,192,907	\$48,769,835
Average # Rxs / Utilizing Member / Month	3.72	3.77
Average Amount Paid / Claim	\$55.67	\$51.66
Average Amount Paid / Utilizing Member	\$207.28	\$194.74
Average Amount Paid / Eligible Member	\$92	\$84.04

# Average Prescription Payment

	Percent of Total Prescriptions		Average Rx Payment	
	1Q2011	1Q2010	1Q2011	1Q2010
Single Source Brand	20.13%	19.62%	\$185.59	\$166.85
Multi-Source Brand	5.6%	6.97%	\$93.92	\$94.45
Generic	74.28%	73.42%	\$17.46	\$16.74

# Utilization Data

## Total Population

# Top 10 Therapeutic Classes By Claim Volume

1Q2011			1Q2010	
Rank 2011	Therapeutic Class	# Claims 2011	Rank 2010	# Claims 2010
1	Narcotic Analgesics	152,406	1	150,803
2	Anticonvulsants	151,545	2	144,224
3	Penicillins	115,528	4	96,382
4	2 <sup>nd</sup> Generation Antihistamines	105,763	3	96,988
5	NSAIDs-COX Inhibitor Type	95,251	7	82,806
6	Anti-Anxiety Drugs	92,866	5	92,423
7	PPIs	88,466	6	88,572
8	Beta-Adrenergic Agents	81,798	8	80,181
9	Macrolides	81,208	12	68,726
10	ADHD Drugs	80,167	10	71,716

# Top 10 Therapeutic Classes By Payment Amount

1Q2011			1Q2010	
Rank 2011	Therapeutic Class	Payment Amount 2011	Rank 2010	Payment Amount 2010
1	Atypical Antipsychotics	\$18,731,374	1	\$16,444,061
2	ADHD Drugs	\$12,213,053	2	\$9,888,517
3	PPIs	\$7,924,013	3	\$7,302,705
4	Anticonvulsants	\$7,877,503	4	\$7,197,431
5	Narcotic Analgesics	\$7,554,734	5	\$7,044,178
6	Leukotriene Receptor Antagonists	\$4,836,458	7	\$4,106,938
7	Insulins	\$4,779,550	6	\$4,195,972
8	Beta-Adrenergic/ICS Combos	\$4,147,722	8	\$3,901,205
9	Statins	\$3,517,344	11	\$3,205,110
10	Beta-Adrenergic Agents	\$3,497,559	9	\$3,307,872

# Top 10 Drugs By Claim Volume

1Q2011			1Q2010	
Rank 2011	Therapeutic Class	# Claims 2011	Rank 2010	# Claims 2010
1	amoxicillin	83,873	2	67,565
2	hydrocodone/APAP	81,534	1	78,587
3	azithromycin	76,428	3	63,758
4	loratadine	58,265	4	59,530
5	ibuprofen	53,756	7	44,057
6	Prilosec <sup>®</sup> OTC	51,846	5	53,859
7	clonazepam	46,329	6	46,474
8	gabapentin	38,674	13	31,189
9	lisinopril	37,583	9	35,506
10	promethazine	37,392	8	37,535

# Top 10 Drugs By Payment Amount

1Q2011			1Q2010	
Rank 2011	Therapeutic Class	Payment Amount 2011	Rank 2010	Payment Amount 2010
1	Nexium®	\$6,134,479	4	\$3,842,875
2	Abilify®	\$5,946,026	1	\$5,023,555
3	Singulair®	\$4,825,186	3	\$4,070,042
4	Seroquel®	\$4,378,790	2	\$4,248,941
5	Synagis®	\$3,366,747	5	\$2,834,071
6	Concerta®	\$3,142,490	10	\$2,350,566
7	Crestor®	\$3,045,180	6	\$2,710,520
8	Suboxone®	\$2,812,929	9	\$2,393,199
9	Advair Diskus®	\$2,677,449	7	\$2,693,072
10	Adderall XR®	\$2,505,674	8	\$2,473,392

# Utilization Data

## Adult Population (Ages $\geq$ 19)

# Top 10 Therapeutic Classes By Claim Volume

1Q2011			1Q2010	
Rank 2011	Therapeutic Class	# Claims 2011	Rank 2010	# Claims 2010
1	Narcotic Analgesics	141,059	1	140,715
2	Anticonvulsant	130,481	2	124,779
3	Anti-Anxiety Drugs	90,577	3	90,700
4	PPIs	77,722	4	78,267
5	Analgesics / Antipyretics	68,390	5	75,313
6	SSRIs	60,431	6	59,525
7	NSAIDs	58,716	7	55,409
8	Statins	52,169	9	49,446
9	2 <sup>nd</sup> Gen Antihistamines	50,757	10	49,116
10	1 <sup>st</sup> Gen Antihistamines	45,986	11	46,404

# Top 10 Therapeutic Classes By Payment Amount

1Q2011			1Q2010	
Rank 2011	Therapeutic Class	Payment Amount 2011	Rank 2010	Payment Amount 2010
1	Atypical Antipsychotics	\$13,091,476	1	\$11,490,846
2	Narcotic Analgesics	\$7,387,838	2	\$6,915,818
3	PPIs	\$6,817,768	3	\$6,278,932
4	Anticonvulsants	\$5,817,207	4	\$5,427,161
5	Insulins	\$4,071,496	5	\$3,603,011
6	Statins	\$3,504,909	6	\$3,194,057
7	Beta Adrenergic/ICS Combos	\$3,277,646	7	\$3,016,641
8	Lipotropics	\$2,466,367	9	\$1,974,614
9	Platelet Inhibitors	\$2,425,875	8	\$2,075,473
10	Antihyperglycemics	\$2,092,028	10	\$1,653,308

# Top 10 Drugs By Claim Volume

1Q2011			1Q2010	
Rank 2011	Therapeutic Class	# Claims 2011	Rank 2010	# Claims 2010
1	hydrocodone/APAP	74,537	1	71,542
2	Prilosec OTC <sup>®</sup>	46,937	2	49,338
3	clonazepam	45,013	3	45,146
4	gabapentin	38,121	8	30,684
5	lisinopril	36,498	5	34,538
6	loratadine	35,324	4	36,510
7	alprazolam	34,007	6	32,004
8	aspirin EC	32,509	7	31,659
9	Nexium <sup>®</sup>	29,412	16	20,233
10	diazepam	26,901	9	26,863

# Top 10 Drugs By Payment Amount

1Q2011			1Q2010	
Rank 2011	Therapeutic Class	Payment Amount 2011	Rank 2010	Payment Amount 2010
1	Nexium®	\$5,261,661	1	\$3,558,791
2	Seroquel®	\$3,498,690	2	\$3,329,926
3	Abilify®	\$3,120,859	4	\$2,563,747
4	Crestor®	\$3,031,271	3	\$2,702,029
5	Suboxone®	\$2,791,649	5	\$2,369,528
6	Plavix®	\$2,246,969	8	\$1,980,171
7	Advair® Diskus	\$2,222,494	6	\$2,178,380
8	Zyprexa®	\$2,167,426	7	\$1,997,896
9	Lyrica®	\$1,791,925	9	\$1,602,298
10	Actos®	\$1,746,995	12	\$1,314,099

# Utilization Data

## Child Population (Ages 0 through 18)

# Top 10 Therapeutic Classes By Claim Volume

1Q2011			1Q2010	
Rank 2011	Therapeutic Class	# Claims 2011	Rank 2010	# Claims 2010
1	Penicillins	91,442	1	74,040
2	ADHD Drugs	74,340	2	66,218
3	Macrolides	57,958	4	47,708
4	2 <sup>nd</sup> Generation Antihistamines	54,599	3	47,866
5	Non-Narc Antitus-1 <sup>st</sup> Gen Antihis-Decongest	46,496	6	40,257
6	Beta Adrenergic Agents	43,007	5	41,927
7	Glucocorticoids	40,082	7	36,489
8	NSAIDs	35,791	9	27,395
9	3 <sup>rd</sup> Gen Cephalosporins	30,359	8	28,344
10	Leukotriene Receptor Antagonists	27,088	11	21,539

# Top 10 Therapeutic Classes By Payment Amount

1Q2011			1Q2010	
Rank 2011	Therapeutic Class	Payment Amount 2011	Rank 2010	Payment Amount 2010
1	ADHD Drugs	\$11,376,259	1	\$9,136,628
2	Atypical Antipsychotics	\$5,407,801	2	\$4,952,273
3	Leukotriene Receptor Antagonists	\$3,370,131	4	\$2,799,488
4	Synagis®	\$3,366,747	3	\$2,834,071
5	Glucocorticoids	\$2,658,848	5	\$2,684,568
6	Anticonvulsants	\$1,929,969	6	\$1,769,513
7	Beta Adrenergic Agents	\$1,888,478	7	\$1,755,390
8	Macrolides	\$1,660,220	8	\$1,337,402
9	Antivirals	\$1,640,218	35	\$219,109
10	3 <sup>rd</sup> Gen Cephalosporines	\$1,629,466	12	\$1,235,555

# Top 10 Drugs By Claim Volume

1Q2011			1Q2010	
Rank 2011	Therapeutic Class	# Claims 2011	Rank 2010	# Claims 2010
1	amoxicillin	69,360	1	54,376
2	azithromycin	55,315	2	45,167
3	ibuprofen	29,402	5	21,552
4	cefdinir	25,971	6	20,576
5	Singulair®	25,805	3	23,745
6	cetirizine	24,073	8	17,646
7	loratadine	22,894	4	23,015
8	albuterol	20,343	7	20,078
9	De-Chlor DM	19,194	18	9,939
10	amox tr-potassium clavulanate	19,013	9	16,988

# Top 10 Drugs By Payment Amount

1Q2011			1Q2010	
Rank 2011	Therapeutic Class	Payment Amount 2011	Rank 2010	Payment Amount 2010
1	Synagis®	\$3,368,819	1	\$2,834,071
2	Singulair®	\$3,363,588	2	\$2,798,579
3	Concerta®	\$3,071,056	5	\$2,299,579
4	Abilify®	\$2,814,720	3	\$2,459,808
5	Vyvanse®	\$2,323,671	6	\$1,815,366
6	Adderall® XR	\$2,254,708	4	\$2,304,732
7	azithromycin	\$1,550,656	7	\$1,253,392
8	Tamiflu®	\$1,525,893	84	\$109,930
9	cefdinir	\$1,444,162	8	\$1,105,754
10	budesonide	\$1,208,997	11	\$1,031,774

# Utilization by Disease States

Total  
Population

# Disease States By Claim Volume

	1Q2011		1Q2010	
	Distinct Recipients	Claim Volume	Distinct Recipients	Claim Volume
Asthma/COPD	128,802	309,602	121,313	297,911
Behavioral Health	102,288	373,341	99,518	359,661
Chronic Pain	89,023	306,986	88,153	300,157
HTN	56,430	211,045	54,687	207,985
Diabetes	18,973	72,287	18,397	72,239
Cancer	5,194	9,493	4,913	9,202
HIV	248	1,179	196	1,000

# Disease States By Payment Amount

Disease	Payment Amount 1Q2011	Payment Amount 1Q2010
Behavioral Health	\$35,742,806	\$30,788,978
Chronic Pain	\$16,444,286	\$15,773,627
Asthma/COPD	\$15,047,648	\$13,811,634
Diabetes	\$8,425,180	\$7,123,721
HTN	\$3,840,188	\$4,147,304
Cancer	\$2,561,913	\$2,426,709
HIV	\$919,513	\$766,911

# Utilization by Disease States

## Adult Population (Ages $\geq$ 19)

# Disease States By Claim Volume

	1Q2011		1Q2009	
	Distinct Recipients	Claim Volume	Distinct Recipients	Claim Volume
Chronic Pain	75,683	277,464	74,885	270,516
Behavioral Health	68,493	251,177	67,501	245,866
Asthma/COPD	51,888	142,408	51,364	143,224
HTN	46,159	186,630	44,907	184,239
Diabetes	17,370	67,550	16,874	67,768
Cancer	4,017	7,942	3,879	7,806
HIV	231	1,094	185	942

# Disease States By Payment Amount

Disease	Payment Amount 1Q2011	Payment Amount 1Q2010
Behavioral Health	\$18,575,124	\$16,209,953
Chronic Pain	\$14,379,397	\$13,847,045
Diabetes	\$7,708,056	\$6,502,170
Asthma/COPD	\$6,186,916	\$5,686,711
HTN	\$3,400,142	\$3,782,216
Cancer	\$2,373,940	\$2,272,705
HIV	\$873,738	\$737,750

# Utilization by Disease States

## Child Population (Ages 0 through 18)

# Disease States By Claim Volume

	1Q2011		1Q2010	
	Distinct Recipients	Claim Volume	Distinct Recipients	Claim Volume
Asthma/COPD	76,964	167,194	70,008	154,687
Behavioral Health	33,911	122,164	32,106	113,795
Chronic Pain	13,419	29,522	13,346	29,641
HTN	10,311	24,415	9,805	23,746
Diabetes	1,613	4,737	1,534	4,471
Cancer	1,178	1,551	1,038	1,396
HIV	17	85	11	58

# Disease States By Payment Amount

Disease	Payment Amount 1Q2011	Payment Amount 1Q2010
Behavioral Health	\$17,167,681	\$14,579,025
Asthma/COPD	\$8,860,733	\$8,124,923
Chronic Pain	\$2,064,889	\$1,926,582
Diabetes	\$717,124	\$621,551
HTN	\$440,046	\$365,089
Cancer	\$187,973	\$154,005
HIV	\$45,775	\$29,161

# Top Ten

# Prescribers

# All Controlled Substances

Prescriber	1Q2011				
	Drugs	Total Cost	Unique Recipients	Avg Drugs Per Recipient	Avg Cost Per Recipient
1	1,467	\$14,699	224	6.55	\$65.62
2	1,970	\$14,938	318	6.19	\$46.98
3	1,508	\$20,459	328	4.6	\$62.37
4	1,662	\$38,139	378	4.4	\$100.90
5	2,930	\$114,719	692	4.23	\$165.78
6	1,784	\$159,459	427	4.18	\$373.44
7	1,915	\$56,449	589	3.25	\$95.84
8	1,686	\$74,797	542	3.11	\$138
9	2,414	\$41,692	989	2.44	\$42.16
10	2,059	\$32,762	854	2.41	\$38.36

# Benzodiazepines

Prescriber	1Q2011				
	Drugs	Total Cost	Unique Recipients	Avg Drugs Per Recipient	Avg Cost Per Recipient
1	528	\$3,116	85	6.21	\$36.66
2	549	\$2,992	106	5.18	\$28.23
3	762	\$3,272	149	5.11	\$21.96
4	541	\$4,089	115	4.7	\$35.56
5	556	\$3,929	163	3.41	\$24.10
6	619	\$4,574	236	2.62	\$19.38
7	595	\$5,429	231	2.58	\$23.50
8	513	\$3,447	214	2.4	\$16.11
9	1210	\$9,745	522	2.32	\$18.67
10	2042	\$20,838	897	2.28	\$23.23

# Narcotic Analgesics

Prescriber	1Q2011				
	Drugs	Total Cost	Unique Recipients	Avg Drugs Per Recipient	Avg Cost Per Recipient
1	1,125	\$25,009	352	3.2	\$71.05
2	829	\$13,344	263	3.15	\$50.74
3	1,155	\$23,396	380	3.04	\$61.57
4	1,511	\$29,601	500	3.02	\$59.20
5	1,167	\$28,565	409	2.85	\$69.84
6	880	\$132,377	313	2.81	\$422.93
7	840	\$55,891	299	2.81	\$186.93
8	827	\$76,230	313	2.64	\$243.55
9	858	\$83,268	328	2.62	\$253.86
10	850	\$58,101	410	2.07	\$141.71

# Long-Acting Narcotic Analgesics

Prescriber	1Q2011				
	Drugs	Total Cost	Unique Recipients	Avg Drugs Per Recipient	Avg Cost Per Recipient
1	293	\$105,029	93	3.15	\$1,129.35
2	221	\$43,981	76	2.91	\$578.71
3	122	\$57,190	44	2.77	\$1,299.78
4	78	\$20,749	30	2.6	\$691.63
5	75	\$26,174	32	2.34	\$817.95
6	78	\$22,324	39	2	\$572.40
7	185	\$51,410	97	1.91	\$530.00
8	134	\$37,960	75	1.79	\$506.13
9	200	\$59,070	112	1.79	\$527.41
10	104	\$20,865	65	1.6	\$321.00

# Short-Acting Narcotic Analgesics



Prescriber	1Q2011				
	Drugs	Total Cost	Unique Recipients	Avg Drugs Per Recipient	Avg Cost Per Recipient
1	761	\$5,403	179	4.25	\$30.18
2	1,113	\$23,607	350	3.18	\$67.45
3	827	\$12,119	262	3.16	\$46.25
4	1,150	\$21,503	379	3.03	\$56.74
5	1,489	\$26,293	498	2.99	\$52.80
6	1,118	\$22,658	404	2.77	\$56.08
7	704	\$19,689	260	2.71	\$75.73
8	792	\$45,312	299	2.65	\$151.54
9	723	\$23,764	321	2.25	\$74.03
10	746	\$37,236	407	1.83	\$91.49

# Prospective Drug Utilization Review (ProDUR)

# Edit Definitions

- **ProDUR Edit** – A computer system review of the member’s medication profile to identify potential drug therapy problems prior to dispensing the medication. Examples would include but not limited to:
  - Therapeutic Duplication (TD), Early Refill (ER), Max Dose, Drug to Gender, Drug to Drug, Drug to Inferred Disease, Geriatric and Pediatric Warnings
  - **Hard Edit** – These edits will cause the claim to deny at the point of sale (POS)
  - **Soft Edit** – These edits will cause an alert or warning message to be returned to the dispensing pharmacist to inform them of a potential problem. The pharmacist can bypass this message to process the claim after further evaluation and/or consultation with the patient or prescriber.

# Edits Currently in POS System

<b>ProDUR Conflict Type</b>	<b>Deny or Message Only</b>	<b>Provider Level Override or PA Required</b>
Drug-to-Drug Interaction (DD)	Deny SL1	PA
Early Refill (ER) 90% tolerance	Deny	PA
Therapeutic Duplication (TD)	Deny	Provider PA-Stimulants
Duplicate Ingredient (ID)	Deny	Provider
Min/Max Daily Dose (LD, HD)	Message	N/A

# ProDUR Summary

	1Q2011	1Q2010
HD, LD	592,043	576,645
DD	1,004,990	942,406
TD	1,181,235	1,136,457
ID	479,443	452,984
ER	353,332	251,776
Total Claims with ProDUR Alerts	1,996,565	1,851,779
Total Claims	3,026,528	2,882,487
<b>% of Claims with ProDUR Alerts</b>	<b>66%</b>	<b>64%</b>
<b>% of Claims with ProDUR Alerts NOT filled.</b>	<b>21%</b>	<b>16%</b>

# Severity Level I Drug-to-Drug Interactions

# Review of Retrospective Drug Utilization Review (RetroDUR) Activities

# RetroDUR Activities

## October 2010 Claims

- PolyPharmacy, >4 Controlled Substances
  - 184 Recipients identified for intervention
  - 344 Prescribers lettered
- Responses returned:
  - 29% response rate
    - Responses with approval ratings:
      - Very Useful = 25%
      - Useful = 36%
      - Somewhat Useful = 7%
      - Neutral = 11%
      - Not Useful = 8%

# RetroDUR Activities

## November 2010 Claims

- $\geq 3200$  mg Ibuprofen
  - 105 Recipients chosen for intervention
  - 117 Prescribers lettered
- Responses returned:
  - 53% response rate
    - Responses with approval ratings:
      - Very Useful = 24%
      - Useful = 24%
      - Somewhat Useful = 5%
      - Neutral = 6%
      - Not Useful = 23%

# RetroDUR Activities

## December 2010 Claims

- Benzodiazepine Duplication
  - 283 Recipients chosen for intervention
  - 380 Prescribers lettered
- Responses returned:
  - 28% response rate
    - Responses with approval ratings:
      - Very Useful = 27%
      - Useful = 23%
      - Somewhat Useful = 4%
      - Neutral = 21%
      - Not Useful = 4%

# Ideas for Future RetroDUR Activities

- Patients with a diagnosis of diabetes and no claim for an ACEI, ARB or Direct Renin Inhibitor in the past 90 days: 8,755
- Patients with a diagnosis of MI and no claim for ASA or Beta Blocker in the past 90 days: 1,068
- Patients with a diagnosis of pregnancy and a claim for a Pregnancy Category D drug in the past 90 days: 1,945
- Varenicline associated with reports of changes in behavior, agitation, depressed mood, suicidal ideation, and attempted/completed suicide: 1,593
- Beers Criteria - Diazepam Use in Older Adults: 1,422
- Enoxaparin: Duration of therapy > 10 days: 451

# Other Ideas for Future RetroDUR Activities

- CAD without Statin: 3,819
- Duplicate long-acting narcotic therapy: 117
- CHF without ACEI/ARB or BB: 3,603
- Combination of clonidine, a benzo and an opiate filled at the same time that are not a hypertensive patient or institutionalized: 224
- Patients taking Plavix + PPI without GI Bleed, PUD, H. pylori, advanced age (>64) or on anticoagulant, oral steroid, or NSAID: 120



# Kentucky Medicaid Drug Management Review Advisory Board (DMRAB) Meeting

**Next Meetings:**

**August 11, 2011**

**November 10, 2011**

**Tina Hawkins, PharmD**

**Clinical Program Manager**

**May 12, 2011**